BACKGROUND AND OBJECTIVES: Potential rectal microbicides, as an adjunct to condoms for HIV/STD prevention, have not been studied previously. GOAL OF THIS STUDY: Advantage 24 (1.5 ml of a bioadhesive gel containing 52.5 mg nonoxynol-9 administered by single-use applicator)-under investigation as a vaginal microbicide-was evaluated for acceptability among male couples. STUDY DESIGN: Twenty-five HIV-negative and 10 HIV-positive male couples participated in a frequency use escalation trial. Diaries and self-administered questionnaires assessed product use, acceptability, sexual behavior, and gastrointestinal and urologic side effects. RESULTS: Excluding participants who felt no need for an HIV prevention method, 58% said they would use Advantage 24 if approved for rectal use; 69% of receptive users reported rectal fullness and related side effects after insertion of the gel, and 68% reported applicator-related discomfort; 59% of insertive participants found the gel too sticky. CONCLUSIONS: Acceptability remains inconclusive and warrants further study of redesigned applicators and ways to minimize rectal side effects.
BACKGROUND AND OBJECTIVES: Potential rectal microbicides, as an adjunct to condoms for HIV/STD prevention, have not been studied previously. GOAL OF THIS STUDY: Advantage 24 (1.5 ml of a bioadhesive gel containing 52.5 mg nonoxynol-9 administered by single-use applicator)-under investigation as a vaginal microbicide-was evaluated for acceptability among male couples. STUDY DESIGN: Twenty-five HIV-negative and 10 HIV-positive male couples participated in a frequency use escalation trial. Diaries and self-administered questionnaires assessed product use, acceptability, sexual behavior, and gastrointestinal and urologic side effects. RESULTS: Excluding participants who felt no need for an HIV prevention method, 58% said they would use Advantage 24 if approved for rectal use; 69% of receptive users reported rectal fullness and related side effects after insertion of the gel, and 68% reported applicator-related discomfort; 59% of insertive participants found the gel too sticky. CONCLUSIONS: Acceptability remains inconclusive and warrants further study of redesigned applicators and ways to minimize rectal side effects.
Authors: Alex Carballo-Diéguez; Rebecca Giguere; Curtis Dolezal; José Bauermeister; Cheng-Shiun Leu; Juan Valladares; Lisa C Rohan; Peter A Anton; Ross D Cranston; Irma Febo; Kenneth Mayer; Ian McGowan Journal: AIDS Behav Date: 2014-09
Authors: Lara E Pereira; Tyana Singletary; Amy Martin; Chuong T Dinh; Frank Deyounks; Angela Holder; Janet McNicholl; Karen W Buckheit; Robert W Buckheit; Anthony Ham; David F Katz; James M Smith Journal: Drug Deliv Transl Res Date: 2018-10 Impact factor: 4.617
Authors: Heather A Pines; Pamina M Gorbach; Robert E Weiss; Kristen Hess; Ryan Murphy; Terry Saunders; Joelle Brown; Peter A Anton; Ross D Cranston Journal: AIDS Behav Date: 2013-03
Authors: Ana Ventuneac; Alex Carballo-Diéguez; Ian McGowan; Robert Dennis; Amy Adler; Elena Khanukhova; Charles Price; Terry Saunders; Chomchay Siboliban; Peter Anton Journal: AIDS Behav Date: 2009-09-11